Here you can see and modify the cookie settings of various tools used on and related subdomains.

Save settings
Advantage Austria Show navigation

Intercell produces new vaccine in Scotland

25. March 2008

Austrian biotech company, Intercell, has begun production of its new vaccine for immunisation against the Japanese Encephalitis virus at its fully owned manufacturing facility in Livingston, Scotland.   

The Austrian biotech company, Intercell, has invested £98 million (EUR 125 million) since 1999 in the developing its vaccine against Japanese Encephalitis (JE). JE is a mosquito-borne flaviviral infection and is the leading cause of childhood encephalitis and viral encephalitis in Asia.

Because JE is a significant and serious public health threat in Asia the initial target for use of the vaccine will be adult civilian travellers and military personnel who visit or are deployed to affected countries, including India, China and South East and South West Asia.

Intercell has completed submissions of regulatory filing with both the US Food and Drug Administration (FDA) and the EMEA (European Medicines Agency). The company has also successfully completed the clinical phase-III pivotal efficacy and safety trials for its lead product and, subject to the validation of the most recent submissions, expects licensures in the US and the EU in 2008.

As a result, Intercell is preparing a launch stock of 300,000 vaccine bottles at its Scottish facility. 

About Intercell

Intercell AG is an Austrian biotechnology company focused on the research, development, manufacturing and future commercialization of innovative vaccines for prevention and treatment of infectious diseases for which there exists substantial unaddressed medical need. The company develops antigens and immunizers (adjuvants) which are derived from its proprietary technology platforms and has in-house GMP manufacturing capability. Intercell has strategic partnerships with a number of global pharmaceutical companies, including Novartis AG, sanofi pasteur S.A. , Merck&Co., Inc., the Statens Serum Institut and Kirin Brewery Co., Ltd. The company employs 250 people worldwide and is listed on the Vienna stock exchange under the symbol "ICLL".   

Related links